ISPE announced its inaugural Conference on Quality Culture and Quality Metrics, taking place 25 – 26 April in Bethesda, Maryland USA. This uniquely focused event will feature high-level sessions, aligned with the FDA’s revised draft guidance on quality metrics and ISPE’s on-going Quality Culture and Quality Metrics Initiatives. In-depth workshops will provide insights on the Six Dimensions Framework in the Cultural Excellence report.
Sustainable production of high quality, available products demand a knowledgeable and devoted mindset to improve quality culture,” said John Bournas, ISPE CEO and President. “This conference was crafted to provide an enriched understanding of how quality metrics and quality culture are used throughout the pharmaceutical industry to monitor quality management systems and processes, and drive continuous improvement efforts in drug manufacturing.
The ISPE Conference on Quality Culture and Quality Metrics will feature a collection of practical, powerful tools and a comprehensive, behavior-based approach for improving quality culture as a means of delivering enhanced quality outcomes. This event will also deliver the latest data and insights for operationalization of quality metrics across the supply chain.
Keynote speakers include:
There will also be a high-level industry panel on quality culture, and special sessions on quality metrics with industry leaders and three FDA experts.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...
